IQVIA’s Orchestrated Customer Engagement (OCE) Solution Adopted by More than 30 Life Sciences Companies in First Year of La...
08 January 2019 - 12:00AM
Business Wire
Three dozen organizations, including two top-20
global pharma companies, select IQVIA Technologies OCE to harmonize
customer interactions and transform commercial model
IQVIA™ (NYSE:IQV) today announced that more than 30 life
sciences companies have selected Orchestrated Customer Engagement
(OCE) as their commercial solution in the 12 months since the
groundbreaking technology first launched. OCE customers include
top-20 global pharmaceutical companies, Novo Nordisk and Roche, as
well as Adhera Therapeutics, Napo Pharmaceuticals, Pierre Fabre
Pharmaceuticals, PruGen Pharmaceuticals, Recordati, and Theramex.
IQVIA launched the new category of cloud-based life sciences
technology on December 12, 2017 - today, OCE is live in 115
countries.
This milestone validates the need within the market for more
sophisticated customer engagement, a need that’s met by OCE’s
innovative solution and the orchestrated commercial model. It also
reflects the value of IQVIA’s platform-of-platforms strategy,
exemplified by our long-term and expanding alliance with Salesforce
to build transformative life science applications across the
product lifecycle.
IQVIA Technologies’ OCE empowers life sciences companies to
evolve their commercial models away from organizational silos. With
OCE, companies can take an integrated approach that coordinates
customer-facing roles to operate as a team, connect all human and
digital touchpoints and create an exceptional, personalized
experience. While applying artificial intelligence and intuitive
user interfaces, the OCE platform reduces friction, enhances
productivity, increases value, and enables better decision-making
across the enterprise, while integrating seamlessly with other
IQVIA solutions such as CRM and Master Data Management.
“The out-of-the-gate adoption of OCE proves that IQVIA has its
finger on the pulse of the market’s technology needs,” said Tal
Rosenberg, senior vice president, Global Technology Solutions for
IQVIA. “We will continue to develop and deliver innovative
technologies to help our customers and HCPs engage more
productively and make better decisions.”
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing the information that helps their customers
drive human health outcomes forward. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical
companies, medical researchers, government agencies, payers and
other healthcare stakeholders tap into a deeper understanding of
diseases, human behaviors and scientific advances, in an effort to
advance their path toward cures. To learn more, visit
www.iqvia.com.
Click here to subscribe to Mobile Alerts for IQVIA.
IQVIAFIN
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190107005336/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com)+1.484.567.6732
Andrew Markwick, IQVIA Investor Relations
(andrew.markwick@iqvia.com)+1.973.257.7144
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2024 to May 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From May 2023 to May 2024